Abbvie Inc.

Chris Chumsae

Chen Wang

Germano Coppola

Zehra Kaymakcalan

Anton Manuilov

Czeslaw H Radziejewskia

Disclosed herein are compositions and methods for the isolation and purification of proteins from a sample. In particular, the present invention relates to compositions and methods for isolating and purifying proteins incorporating a displacement chromatographic step. The present invention is also directed toward pharmaceutical compositions comprising one or more antibodies purified by a method described herein.

Protein purification using displacement chromatography

The present invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods for producing such low AR compositions using displacement chromatography. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF&#x3b1; is detrimental, are also provided.

Low acidic species compositions and methods for producing and using the same using displacement chromatography

Provided are methods for measuring the inherent stability of intrachain disulphide-containing domains (e.g., antibody variable domains) and for optimizing the positioning of intrachain disulphide-containing domains within a protein (e.g., a multispecific binding protein, e.g., a DVD-Ig). Also provided are methods of making multispecific binding proteins (e.g., DVD-Ig molecules) comprising two or more antibody variable domains in which the antibody variable domains are optimally positioned within the multispecific binding proteins to enhance stability of the multispecific binding protein. Multispecific binding proteins optimized using the methods disclosed herein are also provided.

Methods for optimizing domain stability of binding proteins

The present invention is directed to modified antibodies, including anti-TNF&#x3b1; antibodies, in which C-terminal amino acids of heavy chain sequences are modified from a native sequence of proline-glycine-lysine ('PGK') to one that includes a proline positioned between the glycine and lysine, resulting in a C-terminal sequence of proline-glycine-proline-lycine ('PGPK'). The invention further provides methods of producing and using such antibodies.

Growing community of inventors

North Andover, MA, United States of America

Chris Chumsae